KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.
You may also be interested in...
Gestiva Approval Unlikely In FY 09; KV Pharmaceutical Admits Credit Fumbles
Firm halts manufacturing and distribution of nearly all products.
Gestiva Approval Unlikely In FY 09; KV Pharmaceutical Admits Credit Fumbles
Firm halts manufacturing and distribution of nearly all products.
Vivus Gets FDA Approval For Evamist Estradiol Spray
Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.